We first confirmed the status of EGFR as a putative amplified target in ESCC, evaluating data from The Cancer Genome Atlas, where we observed focal amplification of EGFR in 17% of cases (Fig. 1a). Here, EGFR is linked to esophageal squamous cell carcinoma.